stocks logo

CLBT

Cellebrite DI Ltd
$
14.250
-0.24(-1.656%)1D
  • Overview
  • Forecast
  • Valuation
  • Earnings
Line
Line
|
Candle
Candle
1D
5D
1M
3M
6M
YTD
1Y
5Y
High
14.590
Open
14.590
VWAP
--
Vol
1.12M
Mkt Cap
3.41B
Low
14.170
Amount
--
EV/EBITDA(TTM)
43.29
Total Shares
205.30M
EV
3.06B
EV/OCF(TTM)
21.40
P/S(TTM)
7.69
Cellebrite DI Ltd is an Israel-based company engaged primarily in the software sector. The Company is committed to providing a Digital Intelligence (DI) platform for managing DI in legally sanctioned investigations. The Company provides solutions for the public and private sectors, enabling organizations in mastering the complexities of legally sanctioned digital investigations by streamlining intelligence processes. The Company's platform and solutions transform how customers collect, review, analyze and manage data in legally sanctioned investigations. The Company aims to enable its customers to protect and save lives, accelerate justice, and preserve privacy in communities around the world.
Show More

Market Estimates

Earnings Estimates
Revenue
YoY Chg
EPS
YoYChg
FY2025Q4
FY2025Q3
FY2025Q2
130.86M
+20%
0.131
+30.91%
124.36M
+16.38%
0.127
-9.5%
112.21M
+17.23%
0.107
+6.96%
Estimates Revision
The market is revising Downward the revenue expectations for Cellebrite DI Ltd. (CLBT) for FY2025, with the revenue forecasts being adjusted by -1.89% over the past three months. During the same period, the stock price has changed by -27.99%.
Revenue Estimates for FY2025
Revise Downward
down Image
-1.89%
In Past 3 Month
EPS Estimates for FY2025
No Change
down Image
0.00%
In Past 3 Month
Stock Price
Go Down
down Image
-27.99%
In Past 3 Month
7 Analyst Rating
up Image
63.16% Upside
Wall Street analysts forecast CLBT stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for CLBT is 23.25 USD with a low forecast of 20.00 USD and a high forecast of 25.00  USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
7 Buy
0 Hold
0 Sell
Strong Buy
up Image
63.16% Upside
Current: 14.250
sliders
Low
20.00
Averages
23.25
High
25.00
JPMorgan
Overweight
downgrade
$22 -> $20
2025-06-23
Reason
JPMorgan lowered the firm's price target on Cellebrite to $20 from $22 and keeps an Overweight rating on the shares as part of a security software earnings preview. Demand remained relatively healthy for high priority budget categories, with identity and data security increasing in priority, the analyst tells investors in a research note. The firm established 2026 based price targets across its coverage for those that have not yet been updated.
JPMorgan
Overweight
downgrade
$29 -> $25
2025-05-12
Reason
JPMorgan lowered the firm's price target on Cellebrite to $25 from $29 and keeps an Overweight rating on the shares. The firm cites recent peer multiple contraction for the target cut. Cellebrite has the greatest level of government and federal exposure within the sector, which continues to pressure the stock, the analyst tells investors in a research note. However, JPMorgan remains optimistic on the shares, saying industry conversations reflect strong demand from spending initiatives Cellebrite has exposure to, implying concerns are likely overdone.
Needham
Mike Cikos
Strong Buy
Reiterates
$28
2025-04-02
Reason
Needham
Mike Cikos
Strong Buy
Reiterates
$28
2025-03-27
Reason
Needham
Mike Cikos
Strong Buy
Reiterates
$28
2025-03-10
Reason
Needham
Mike Cikos
Strong Buy
Reiterates
$28
2025-02-14
Reason

Valuation Metrics

The current forward P/E ratio for Cellebrite DI Ltd (CLBT.O) is 30.34, compared to its 5-year average forward P/E of 46.79. For a more detailed relative valuation and DCF analysis to assess Cellebrite DI Ltd 's fair value, click here.

Forward PE

StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
Fair
5Y Average PE
46.79
Current PE
30.34
Overvalued PE
71.58
Undervalued PE
21.99

Forward EV/EBITDA

StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
Fair
5Y Average EV/EBITDA
26.08
Current EV/EBITDA
23.81
Overvalued EV/EBITDA
39.55
Undervalued EV/EBITDA
12.60

Forward PS

StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
Fair
5Y Average PS
5.04
Current PS
6.99
Overvalued PS
7.56
Undervalued PS
2.51

Financials

Annual
Quarterly
FY2025Q1
YoY :
+20.06%
107.55M
Total Revenue
FY2025Q1
YoY :
+32.54%
12.27M
Operating Profit
FY2025Q1
YoY :
-124.38%
17.40M
Net Income after Tax
FY2025Q1
YoY :
-119.44%
0.07
EPS - Diluted
FY2025Q1
YoY :
+134.05%
18.54M
Free Cash Flow
FY2025Q1
YoY :
-1.70%
83.74
Gross Profit Margin - %
FY2025Q1
YoY :
+19.48%
31.53
FCF Margin - %
FY2025Q1
YoY :
-120.31%
16.18
Net Margin - %
FY2025Q1
N/A
ROIC

Trading Trends

Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
0.0
USD
0
3-6
Months
0.0
USD
0
6-9
Months
0.0
USD
0
0-12
Months
0.0
USD
0
Bought
0-3
0
0.0
USD
Months
3-6
0
0.0
USD
Months
6-9
0
0.0
USD
Months
0-12
0
0.0
USD
Months
Hedge Fund
Hedge Funds are Neutral. There are no significant trading trends over the last quarter.
Sold
0-3
Months
0.0
Volume
0
3-6
Months
5.0K
Volume
1
6-9
Months
8.6K
Volume
1
0-12
Months
0.0
Volume
0
Bought
0-3
0
0.0
Volume
Months
3-6
0
0.0
Volume
Months
6-9
4
866.4K
Volume
Months
0-12
0
0.0
Volume
Months
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
0.0
USD
0
3-6
Months
0.0
USD
0
6-9
Months
0.0
USD
0
0-12
Months
0.0
USD
0
Bought
0-3
0
0.0
USD
Months
3-6
0
0.0
USD
Months
6-9
0
0.0
USD
Months
0-12
0
0.0
USD
Months

CLBT News & Events

Events Timeline

2025-07-23 (ET)
2025-07-23
08:39:31
Cellebrite announces U.S. DOJ to sponsor platform for FedRAMP ATO
select
2025-07-08 (ET)
2025-07-08
08:51:00
Cellebrite names David Barter as CFO
select
2025-06-05 (ET)
2025-06-05
07:32:27
Cellebrite to acquire Corellium for enterprise value of $170M in cash
select
Sign Up For More Events

News

4.0
07-10TipRanks
3 Best Stocks to Buy Now, 7/10/2025, According to Top Analysts
5.0
07-08NASDAQ.COM
Cellebrite Appoints David Barter To Succeed Dana Gerner As CFO
7.5
06-24Newsfilter
Accelerating Child Exploitation Investigations: Cellebrite Integrates Data from the National Center for Missing and Exploited Children (NCMEC)
Sign Up For More News

FAQ

arrow icon

What is Cellebrite DI Ltd (CLBT) stock price today?

The current price of CLBT is 14.25 USD — it has decreased -1.66 % in the last trading day.

arrow icon

What is Cellebrite DI Ltd (CLBT)'s business?

arrow icon

What is the price predicton of CLBT Stock?

arrow icon

What is Cellebrite DI Ltd (CLBT)'s revenue for the last quarter?

arrow icon

What is Cellebrite DI Ltd (CLBT)'s earnings per share (EPS) for the last quarter?

arrow icon

What changes have occurred in the market's expectations for Cellebrite DI Ltd (CLBT)'s fundamentals?

arrow icon

How many employees does Cellebrite DI Ltd (CLBT). have?

arrow icon

What is Cellebrite DI Ltd (CLBT) market cap?